Berkshire Hathaway's third quarter 2026 earnings show cash and Treasury bills down to $352.3 billion as buybacks continued ...
The report estimates 27 million tonnes of reserves containing 2.0 million ounces of gold, up 38% in tonnage from the Jan. 1, ...
Objective salivary flow rose at least 50% from baseline in 33% on high-dose nipocalimab versus 16% on placebo; two Phase 3 ...
Bloom Energy (NYSE: BE) donated $10,000 to the Firefighter Community Fund during a visit to Oxford, Mississippi, ahead of Georgia-Ole Miss. The nonprofit, established by Oxford Fire Department members ...
AST SpaceMobile (ASTS) plans to build its own 20-ton Blacklift rocket using engines from Firefly Aerospace (FLY) for satellite deployment. Designed for reusability, Blacklift would carry up to five ...
Gilead Sciences (Nasdaq: GILD) reported higher one-year persistence with twice-yearly lenacapavir than daily oral F/TDF in the PURPOSE 5 HIV-prevention trial. Persistence means consistent, continuous ...
Critical Metals (Nasdaq: CRML) completed its acquisition of European Lithium through court-approved schemes, making European Lithium a wholly owned subsidiary. Eligible holders received 0.045 new CRML ...
From the moment an official company press release is issued until Stock Titan has processed it, scored it and sent it to the live feed, on average under 50 milliseconds pass. What a reader sees ...
Supermicro (NASDAQ: SMCI) launched a shared AI inference storage solution with IBM and NVIDIA that stores previously computed context for reuse. The system combines Supermicro Petascale servers, IBM ...
SEALSQ (NASDAQ: LAES) signed a collaboration agreement with Geneva-based TechAgency to help organizations assess and execute their transition to post-quantum security. The planned joint offering ...
FingerMotion (FNGR) signed binding agreements with Genius Group and BlueFlare for an Alberta computing campus program covering up to 100 MW. Campus companies will be owned 75% by FingerMotion and 25% ...
AIM ImmunoTech (AIM) outlined a proposed strategy to investigate Ampligen alongside daraxonrasib or as maintenance after daraxonrasib in pancreatic cancer. The strategy is not an established clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results